Abbonarsi

Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy - 05/11/19

Doi : 10.1016/j.jaci.2019.07.028 
Sarita U. Patil, MD a, b, c, d, , Johanna Steinbrecher, BS a, Agustin Calatroni, MS e, Neal Smith, MS a, Alex Ma, BS a, Bert Ruiter, PhD a, b, c, d, Yamini Virkud, MD, MPH a, b, d, Michael Schneider, BS f, Wayne G. Shreffler, MD, PhD a, b, c, d
a Food Allergy Center, Massachusetts General Hospital, Boston, Mass 
b Harvard Medical School, Boston, Mass 
c Center for Immunology & Inflammatory Diseases, Massachusetts General Hospital, Boston, Mass 
d Food Allergy Science Initiative at Broad Institute at Massachusetts Institute of Technology and Harvard, Boston, Mass 
e Rho, Chapel Hill, NC 
f BÜHLMANN Laboratories, Schönenbuch, Switzerland 

Corresponding author: Sarita U. Patil, MD, 55 Fruit St, Cox 201, Boston, MA 02114.55 Fruit St, Cox 201BostonMA02114

Abstract

Background

Only some patients with peanut allergy undergoing oral immunotherapy (OIT) achieve sustained clinical response. Basophil activation could provide a functional surrogate of efficacy.

Objective

We hypothesized that changes in basophil sensitivity and area under the curve (AUC) to the immunodominant allergen Ara h 2 correlate with clinical responses to OIT.

Methods

Children with peanut allergy aged 7 to 13 years were enrolled in a single-center, open-label peanut OIT trial. Levels of specific immunoglobulins were measured throughout OIT. Peripheral blood from multiple time points was stimulated in vitro with peanut allergens for flow cytometric assessment of the percentage of CD63hi activated basophils.

Results

Twenty-two of 30 subjects were successfully treated with OIT; after avoidance, 9 achieved sustained unresponsiveness (SU), and 13 had transient desensitization (TD). Basophil sensitivity, measured by using the dose that induces 50% of the maximal basophil response, to Ara h 2 stimulation decreased from baseline in subjects with SU (after OIT, P = .0041; after avoidance, P = .0011). At 3 months of OIT, basophil sensitivity in subjects with SU decreased from baseline compared with that in subjects with TD (median, 18-fold vs 3-fold; P = .01), with a receiver operating characteristic of 0.84 and optimal fold change of 4.9. Basophil AUC to Ara h 2 was suppressed after OIT equally in subjects with SU and those with TD (P = .4). After avoidance, basophil AUC rebounded in subjects with TD but not those with SU (P < .001). Passively sensitized basophils suppressed with postavoidance SU plasma had a lower AUC than TD plasma (6.4% vs 38.9%, P = .03).

Conclusions

Early decreases in basophil sensitivity to Ara h 2 correlate with SU. Basophil AUC rebounds after avoidance in subjects with TD. Therefore, different aspects of basophil activation might be useful for monitoring of OIT efficacy.

Il testo completo di questo articolo è disponibile in PDF.

Graphical abstract




Il testo completo di questo articolo è disponibile in PDF.

Key words : Basophil activation, immunotherapy, immunoglobulin, oral immunotherapy, food allergy, peanut allergy, Ara h 2, IgE, IgG4

Abbreviations used : AUC, ED50, OIT, SU, TD


Mappa


 This work was supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (grant K23AI121491 to S.U.P.); the American Academy of Allergy, Asthma & Immunology/Food Allergy Research Education; the 2012 Howard Gittis Memorial 3rd/4th Year Fellowship/New Faculty Research Award (to S.U.P.), and research support from BÜHLMANN Laboratories AG (to W.G.S.). The clinical trial work was performed in the Harvard Clinical and Translational Science Center supported by grants 1UL1TR001102 and 8UL1TR000170 from the National Center for Advancing Translational Sciences and 1UL1 RR025758 from the National Center for Research Resources. Cytometry performed in the MGH Department of Pathology Flow and Image Cytometry Research Core was supported by the NIH Shared Instrumentation program with grants 1S10OD012027-01A1, 1S10OD016372-01, 1S10RR020936-01, and 1S10RR023440-01A1.
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2019  American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 144 - N° 5

P. 1310 - novembre 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • Deriving individual threshold doses from clinical food challenge data for population risk assessment of food allergens
  • Joost Westerhout, Joseph L. Baumert, W. Marty Blom, Katrina J. Allen, Barbara Ballmer-Weber, René W.R. Crevel, Anthony E.J. Dubois, Montserrat Fernández-Rivas, Matthew J. Greenhawt, Jonathan O'B. Hourihane, Jennifer J. Koplin, Astrid G. Kruizinga, Thuy-My Le, Hugh A. Sampson, Wayne G. Shreffler, Paul J. Turner, Steve L. Taylor, Geert F. Houben, Benjamin C. Remington
| Articolo seguente Articolo seguente
  • Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization
  • Edwin H. Kim, Luanna Yang, Ping Ye, Rishu Guo, Quefeng Li, Michael D. Kulis, A. Wesley Burks

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.